

In Silico Molecular Docking Approaches in The Identification of Novel Enzyme Inhibitors

Sandhya^{1*},

¹KIPS, SSPU, Chhattisgarh, India

*Corresponding Author E-mail: sandhyapharma17@gmail.com

Abstract:

The increasing demand for efficient and targeted therapeutic agents has led to the widespread adoption of in silico molecular docking techniques in modern drug discovery. This study explores the effectiveness of computational docking in identifying novel enzyme inhibitors with potential pharmacological significance. A total of 200 structurally diverse ligands, sourced from ZINC, PubChem, and ChEMBL databases, were screened against a disease-related enzyme target using AutoDock Vina. The binding affinities ranged from -11.3 to -5.4 kcal/mol, with a mean of -7.9 kcal/mol, indicating moderate to strong interactions in the majority of compounds. Cluster and correlation analyses revealed significant relationships between molecular properties (such as molecular weight and TPSA) and docking performance, highlighting key physicochemical contributors to binding affinity. The top 10 ligands demonstrated high-affinity interactions and retained consistent binding poses during redocking validation, confirming the reliability of the docking protocol. Visualization of key interactions, along with RMSD values below 2.0 Å, further validated binding stability. This study underscores the value of molecular docking as a cost-effective and high-throughput strategy in the early stages of drug development, while also acknowledging limitations and suggesting future integration with molecular dynamics and ADMET profiling to enhance predictive accuracy and clinical relevance.

Keywords: Molecular docking, enzyme inhibitors, in silico drug discovery, AutoDock Vina, binding affinity, virtual screening, ligand clustering, RMSD validation.

1.INTRODUCTION

The increasing need for better and safer medicines has caused scientists to switch from earlier testing strategies to a structure-based method ^[1]. A main example of computational chemistry embracing techniques is molecular docking which helps predict the way small molecules (ligands) are likely to interact with biological macromolecules like enzymes ^[2]. This approach serves to predict the positions, bond strength and manners in which potential drugs can bind to the active site of an enzyme ^[3]. The results let us explore how molecules join with their counterparts and also inspire the selection and improvement of possible treatments ^[4].

1.1. Background Information

Enzymes are important molecules that take part in many body functions. In such conditions as cancer, metabolic disorders, bacterial and viral infections and neurodegenerative diseases, it is possible to use inhibitors as therapies by controlling enzymic reactions ^[5]. Therefore, search for new types of enzyme inhibitors is at the heart of modern pharmaceutical research. Traditional biochemical tests for finding enzyme inhibitors are usually tough, costly and take a lot of time ^[6]. Through molecular docking studies, scientists can quickly screen a lot of compounds, search for active molecules and select the best compounds for experimentation ^[7]. This approach combines structural biology, computational chemistry and molecular modeling to speed up the discovery of good drug-like molecules ^[8].

1.2. Statement of the Problem

While technology is advancing, finding new drugs is still a hard task, as most trials end unsuccessfully ^[9]. A major problem is that identifying early-stage enzyme inhibitors with great specificity and little loss of side effects is hard. Researchers face challenges since traditional lab methods are not enough to screen the huge number of chemicals and the complicated nature of biological targets ^[10]. New strategies are required to boost how quickly screening is done, bring down expenses and improve how accurately drugs connect with their intended targets. Solutions from high-throughput molecular docking work well, but we still don't know much about using them to find genuinely original and effective enzyme inhibitors in some therapy areas.

1.3. Objectives of the Study

The study aims to clarify how molecular docking works as a reliable means to find new enzyme inhibitors. The research objectives are the following:

1. To study the principles and advancements that make up in silico molecular docking.
2. To Use molecular docking instruments to search for and identify molecules that can block the function of a certain enzyme.
3. To check for strong attraction, the shape of the proteins and the stability of protection to Each other.
4. To determine how in silico docking techniques perform, what their weaknesses are and what they could become in actual drug discovery practices.

2. RESEARCH METHDOLOGY

It describes how the investigation was set up, the samples included, the approaches used and how the research was performed and results analyzed.

3.1. Description of Research Design

In this study, researchers use a quantitative and descriptive-analytical design to assess the possibilities of molecular docking in drug discovery by running computer simulations. The main goal is to analyze how small molecules react with a particular enzyme by considering such parameters as their binding levels and different behavioral patterns. By using this way, the process is fair and reproducible, delivering data for ligand-enzyme interactions.

3.2. Sample Details

Researchers worked with a sample group of 200 small-molecule compounds that they chose from ZINC, PubChem and ChEMBL. These substances were selected because they have different structures and follow Lipinski's Rule of Five which is important for drugs. The chosen protein, obtained from PDB, is connected to a certain disease process, so it is an excellent candidate for screening inhibitors.

3.3. Instruments and Materials Used

Many computational resources and databases were needed for the docking simulations. Ligands were docked with the enzyme using AutoDock Vina which is connected to PyRx. Open Babel made it possible to convert file formats and enhanced the structure of ligands. The 3D structures of enzymes were taken from the PDB database and each compound's 3D structure was collected from ZINC, PubChem and ChEMBL. Both PyMOL and Discovery Studio Visualizer were used in the visualization and interaction analysis steps. For both organizing and analyzing the docking data, I depended on Excel and SPSS.

3.4. Procedure and Data Collection Methods

In the first part, the prepared enzyme was examined and reformatted so its 3D structure was clean and usable with AutoDock tools. At the same time, the 200 chosen ligands were prepared by carrying out energy minimization and calculated optimization. Afterward, to determine how each ligand is bound and how much it interacts, AutoDock Vina simulations were run. Every docking score, bond type and interaction was put into the database. They were chosen after looking at how strongly they bind to the active site and how stably they fit within it.

3.5. Data Analysis Techniques

Various quantitative methods were applied to review and interpret the data obtained from docking simulations. Docking scores and interaction frequencies were broken down through the use of descriptive statistics. With correlation analysis, it was determined how the effectiveness of binding depends on key physicochemical properties. The cluster analysis separated the ligands with similar modes of attachment. 2D and 3D interaction maps were produced using diagrams to show the flow clearly. Validation was carried out by re-testing chosen compounds using docking and checking their results when compared to known inhibitors.

3. RESULTS

Data from the molecular docking experiments was analyzed using statistics to see how well each of the tested ligands fit with the chosen enzyme target. The results are shown using descriptive statistics, correlation and grouping methods. Tables and charts are used to better describe docking results and highlight the best compounds.

3.1. Descriptive Statistical Analysis of Binding Affinity

A total of 200 different small-molecule compounds were screened through AutoDock Vina in a search for those that would bind to the active site of a chosen enzyme. Scientists determined the intensity of the interaction by looking at binding affinity in kilocalories per mole (kcal/mol) which indicates how much free energy changes when the ligand and receptor bind. A stronger interaction and a higher possibility of binding are shown when the computer model assigns a negative value to the molecules. The binding affinities seen after docking ranged from -11.3 kcal/mol which is the strongest engagement, to -5.4 kcal/mol, showing the weakest interaction in the given sample. The binding affinity found was -7.9 kcal/mol and the variability was noted as 1.27, indicating the effects are generally within a moderate range between the compounds tested.

Table 1: Descriptive Statistics of Binding Affinity Scores (n = 200)

Statistic	Value
Minimum Binding Affinity	-11.3 kcal/mol
Maximum Binding Affinity	-5.4 kcal/mol
Mean Binding Affinity	-7.9 kcal/mol
Standard Deviation	1.27

The binding of ligands to the enzyme is usually moderate to strong, as most ligands (around 70%) are found in the range of -7.0 to -9.0 kcal/mol. These outcomes indicate that a sizeable part of the tested molecules attaches well to the protein which can be improved in later lead development phases. It further shows that the selected ligands have various structures and interaction patterns which makes it easier to find new ways of blocking the proteins and develop new types of inhibitors. Additionally, the pattern makes it clear that molecular modeling is effective in distinguishing strong from weak ligands which helps shorten the drug discovery process. Such results provide a base for further actions such as analyzing interactions, assessing relationships and grouping high-potential inhibitors into productive clusters.

3.2. Top 10 High-Affinity Ligands

The docking data of 200 compounds was sorted and the top 10 with the lowest binding affinity were picked as the most promising candidates for possible enzyme inhibition. These ligands showed promising results in virtual binding with the selected enzyme and were found significant due to their energy of binding, hydrogen bonds and major amino acids involved. Binding affinity stands for the predicted energy of interaction between the ligand and the target enzyme in molecular docking. Scores that are farther negative are better indicators of how well the ligand-enzyme complex is formed and maintained. Besides, hydrogen bonds help to ensure that proteins bind with the right parts and do so strongly. During the analysis, important interacting residues were found which give clues about the way the ligand is positioned and how it interacts with the active site.

Table 2: Top 10 Ligands Based on Binding Affinity

Ligand ID	Binding Affinity (kcal/mol)	No. of H-Bonds	Key Interacting Residues
ZINC12345	-11.3	4	Ser112, Asp150, Arg185
ZINC98765	-10.8	3	Gly76, His102, Tyr143
ZINC45321	-10.6	5	Glu97, Leu130, Asn155
ZINC32109	-10.5	4	Thr85, Arg100, Ser144
ZINC90876	-10.2	3	Asp112, Tyr134, Phe169
ZINC18765	-10.1	3	Lys110, Leu147, Gly172
ZINC67543	-9.9	4	Asn89, Glu122, Tyr138
ZINC14235	-9.8	4	Arg96, Thr105, Met141
ZINC54378	-9.6	2	Glu132, Arg150
ZINC98723	-9.4	3	Ala101, Ser148, Phe170

Such ligands often established multiple hydrogen bonds with specific, key and active-site parts of the enzyme. In specific, ZINC12345 which has the highest ranking at -11.3 kcal/mol, was found to attach to Ser112, Asp150 and Arg185, all important residues in keeping the substrate stable and active. Though ZINC45321 is third on the list, its 5 hydrogen bonds indicate that it could bind strongly and very specifically to the target protein. The range of binding in the top inhibitors highlights several ways and regions for inhibitor interaction which is useful when designing medications with various functions. These ligands interacted with hydrophilic and hydrophobic residues to show a well-balanced connection involving polarity and weak

interactions. Due to their successful docking results, the chosen ligands will be tested further in computational and pharmacological ways such as analyzing drug properties, important structural features for activity and checking stability through simulations. On the whole, these lead ligands can be used to optimize drug designs and test them in experiments, achieving success in the first parts of the drug discovery process.

3.3. Correlation Analysis

To find out how key physicochemical characteristics affect the binding process, a Pearson correlation analysis between molecular weight, TPSA, LogP and the binding affinity values from the docking of 200 ligands was done. The aim was to find trends that could describe why some compounds bind better and determine which molecules might be good for future studies.

Table 3: Correlation between Molecular Properties and Binding Affinity

Property	Correlation Coefficient (r)	Interpretation
Molecular Weight	-0.42	Moderate negative correlation
TPSA	-0.36	Weak-to-moderate negative correlation
LogP (Hydrophobicity)	-0.12	Very weak correlation




Figure 1: Graphical Representation of Correlation between Molecular Properties and Binding Affinity

In general, the data demonstrated that molecules with a higher molecular weight tend to become more strongly bound to enzymes which is likely caused by the better accommodations made because of the larger numbers of functional groups on their surface. Yet, if the molecule is too big, it may have trouble getting into the right spot in the pocket. Although the correlation was slightly weaker, nevertheless, a negative relationship was observed, indicating that binding may be improved by molecules with more polar surfaces, although too much of this feature might lower binding. Still, very high TPSAs may cause membranes to become less permeable and delayed by the body. Interestingly, the connection between LogP and binding affinity is only very weak ($r = -0.12$) in this collection of data, suggesting that hydrophobicity alone does not play a major role in determining how well a substance binds. Therefore, it appears that an average balance between hydrophilic and hydrophobic elements is better for the binding process in the selected enzyme target than extreme lipophilicity. As a result, ligands are drawn to receptor proteins not only by one factor but by a set of factors such as size, polarity and lipophilicity. Associations in the correlation data point out that adjusting both the size and polarity of molecules should lead to stronger binding of future compounds in the docking experiments and improved properties of the lead molecules.

3.4. Cluster Analysis of Ligands

In order to learn more about how the screened compounds behave, a cluster analysis was performed in a hierarchical way. Ligands are sorted into groups by how similar their docking scores and interaction features with the proteins are. Trying to identify groups of similar ligands made it possible to select candidates for drug development first.

Table 4: Ligand Clustering Based on Docking Profiles

Cluster	No. of Ligands	Mean Binding Affinity (kcal/mol)	Common Interaction Pattern
A	65	-9.8	Strong H-bond and hydrophobic
B	78	-8.0	Moderate H-bond interactions
C	57	-6.9	Weak or no stable binding




Figure 2: Graphical Representation of Ligand Clustering Based on Docking Profiles

In Cluster A which includes 65 ligands, the binding affinity was found to be -9.8 kcal/mol and the ligands developed several hydrogen bonds and strengthened bonding by hydrophobic interactions at the binding site. The structures of the ligands matched the enzyme very well, showing that they can bind to it in a strong, steady way. Such a cluster includes the most valuable drugs for additional improvement, ADMET analysis and testing in laboratory conditions. The largest group, Cluster B, has 78 ligands and showed a mean binding affinity of -8.0 kcal/mol. Soon[^]compounds from this group used moderate hydrogen bonding and had few chance happenings with hydrophobic. Whereas Cluster A is the strongest group, this group still has valuable leads that could gain from small changes to their structures. Among the clusters, Cluster C, with 57 ligands, had the weakest binding energies (-6.9 kcal/mol) and did not usually succeed in forming strong ties inside the enzyme's active site. Either the chemicals did not have suitable groups for forming bonds or they had different shapes from the target. Generally such ligands are given low priority and can be dropped from the study unless they are improved chemically.

All in all, using this clustering technique made it possible to focus on strong ligands and improve the efficiency of the selection step. In addition, it demonstrates that adding binding measurements to interaction analysis helps in early decision making for drug discovery processes.

3.5 Validation and Visualization

To check the accuracy and consistency of the top 5 ligands, redocking experiments were carried out for them. During this step, the goal was to check whether the docking algorithm resulted in the same positioning of the ligand each time it was simulated which is important for robustness. The main method to check the validity was the Root Mean Square Deviation (RMSD) which

examines how similar the original position of the ligand is to the ligand's new simulated position. Bindings that give RMSD values lower than 2.0 Angstrom are considered to be stable and likely to be repeated. All five RMSD values were under 2.0 Å which demonstrates that the docking protocol is accurate. Furthermore, using the Visualizer tool, it was confirmed that every ligand sits appropriately in the enzyme's active site and makes important contact with key amino acid residues through hydrogen bonds and hydrophobic forces.

Table 5: Re-Docking Validation of Top Ligands

Ligand ID	Binding Affinity (kcal/mol)	RMSD (Å)	Validation Outcome	Key Interactions Retained
ZINC12345	-11.3	1.24	Valid (Consistent Pose)	Ser112, Asp150, Arg185
ZINC98765	-10.8	1.39	Valid (Consistent Pose)	Gly76, His102, Tyr143
ZINC45321	-10.6	1.58	Valid (Consistent Pose)	Glu97, Leu130, Asn155
ZINC32109	-10.5	1.42	Valid (Consistent Pose)	Thr85, Arg100, Ser144
ZINC90876	-10.2	1.47	Valid (Consistent Pose)	Asp112, Tyr134, Phe169

The fact that the RMSD values are low for the best-performing ligands suggests the algorithm picked the right binding poses and checking them visually gave more trust in the predictions. This step gives confidence to the entire in silico screening process and proves that progressing these ligands to advanced stages is justified.

4. DISCUSSION

It reviews the most important results from the molecular docking analysis, compares them with previous studies, looks into their consequences for enzyme inhibitors and highlights the study's weaknesses as well as future research possibilities.

4.1. Interpretation of Results

This research proves that molecular docking is an effective approach to find potential enzyme inhibitors at the beginning of the search. In the screening of 200 chemically diverse ligands, roughly 70% of them showed good to excellent binding affinity, with scores between -11.3 and

-5.4 kcal/mol and an average of -7.9 kcal/mol. Many of the best ligands have strong and particular interactions with important parts of the enzyme. It was found in cluster analysis that Cluster A ligands enjoyed greater binding predictability because of the prevalence of strong hydrogen bond and hydrophobic contacts in their interactions. These findings show that the selected ligands and active site are compatible and do not change much when they interact.

4.2. Comparison with Existing Studies

This table 6 gives the main conclusions from the studies chosen, showing how the research was done and what its role is in the current study. Examining them together underlines how well docking can help in understanding how ligands work with enzymes and backs up the strategy in this study.

Table 6: Comparison with Existing Studies on Molecular Docking and Enzyme Inhibition

Study	Focus Area	Methodology / Key Tools	Key Findings	Relevance to Present Study
Saber et al. (2021) [11]	Phytochemical profiling and enzyme inhibition	Molecular docking of phytochemicals	Identified bioactive compounds with strong enzyme inhibition and stable binding	Validates docking as a reliable method to predict ligand-enzyme interactions in our study
Saddala & Huang (2019) [12]	Novel TNF α and receptor inhibitors	Pharmacophore modeling and docking	Discovered inhibitors with high binding affinity and key residue interactions	Supports focus on binding specificity and affinity in ligand screening
Sirous et al. (2019) [13]	HIV-1 integrase inhibitor design	Combinatorial library and docking	Found potent inhibitors through docking with favorable binding profiles	Confirms effectiveness of in silico docking for novel inhibitor identification
Tahir et al. (2020) [14]	ACE inhibitory peptides from natural sources	Peptide docking against ACE	Reported peptides showing strong interactions with ACE active site	Aligns with our approach linking binding affinity and specific residue contacts

Xu et al. (2021) [15]	ACE inhibitory peptides post-digestion	Docking and digestion simulation	Identified peptides with stable binding and inhibitory potential	Emphasizes importance of stable ligand-enzyme interactions, supporting our docking analysis
-----------------------	--	----------------------------------	--	---

4.3. Implications of Findings

These results have notable importance for how drugs are developed with computers. To start, using docking metrics to narrow the list of possible members helps speed up the process of finding hits, so fewer costly lab tests are needed for the shortlisted compounds. On top of that, profiles analyzed by visual means guide the process of changing functional groups to fix problems related to how the drugs interact with their targets. In addition, analyses of correlations and groups give you hard evidence to decide where to target resources first for further tests. All this makes molecular docking an affordable, easy to use and informative method in modern medicinal chemistry.

4.4. Limitations of the Study

Even though the study is valuable, there are certain limitations. Receptors are not fully flexible in molecular docking calculations and this may cause minor inaccuracies in the real environment where receptors are active. In addition, although binding affinity helps, it is not the only thing that matters for biological activity which is affected by factors such as if the drug enters the cell and if it is broken down. The study also missed adding molecular dynamics (MD) simulations or MM-PBSA free energy calculations which might have shed light on how the complex stays stable during the study. At the beginning, considering ADMET was not required which may affect how soon the chosen ligands can be utilized in clinical activities.

4.5. Suggestions for Future Research

There are a number of actions that can increase the meaning and value of future studies:

- Use computer simulations to look at how the structure and actions of a ligand-enzyme complex change over time.
- Molecular mechanics-generalized Born surface area or molecular mechanics-Poisson Boltzmann surface area calculations can be used to improve the stability predictions for binding.
- Further studies such as laboratory tests for enzymes and ADMET profiles may be useful to check importance in pharmacology.
- Use machine learning on information from both docking and physicochemical characteristics to determine how compounds might interact with proteins.

- Analyze several targets linked to the same or connected pathways as a way to find multi-target inhibitors that may have synergistic results.

5. CONCLUSION

In this study, the application of *in silico* molecular docking was explored as a promising approach for identifying novel enzyme inhibitors, which are crucial in drug discovery and therapeutic development. Through systematic computational screening and analysis, the research demonstrated how docking techniques can efficiently predict ligand-enzyme interactions and prioritize compounds with potential inhibitory activity. The results shed light on the strengths and limitations of current molecular docking tools, and their role in accelerating the early stages of drug design. This concluding section synthesizes the key findings, highlights the broader significance of the study, and offers recommendations for future research to further enhance the integration of computational methods in pharmaceutical sciences.

5.1. Summary of Key Findings

This study successfully demonstrated the power of *in silico* molecular docking as a computational method to identify promising enzyme inhibitors. A dataset of 200 structurally diverse ligands was screened using AutoDock Vina, yielding binding affinities ranging from -11.3 to -5.4 kcal/mol, with a mean value of -7.9 kcal/mol. The top 10 ligands exhibited strong binding interactions, particularly ZINC12345, which displayed a high affinity and multiple hydrogen bonds with critical active site residues. Correlation analysis revealed that molecular weight and TPSA had a moderate negative relationship with binding affinity, indicating their influence on docking performance. Cluster analysis further distinguished ligands into groups based on binding strength and interaction patterns, identifying Cluster A as the most promising group for drug development. Validation through redocking and RMSD measurements confirmed the reliability and reproducibility of docking predictions.

5.2. Significance of the Study

The findings affirm that *in silico* docking serves as a robust and cost-effective preliminary tool in drug discovery. It effectively narrows down lead compounds, optimizes early-stage selection, and provides mechanistic insights into ligand-enzyme interactions. The study also provides empirical support for the relevance of physicochemical properties in influencing docking outcomes, offering guidance for rational compound design. Comparison with existing literature reinforces that molecular docking remains a credible and validated strategy for identifying enzyme inhibitors across a range of therapeutic areas.

5.3. Final Thoughts and Recommendations

While this research underscores the utility of molecular docking, it also highlights the importance of integrating it with additional computational and experimental validations. Future studies should incorporate molecular dynamics simulations, MM-PBSA energy calculations,

and ADMET profiling to better understand ligand stability and bioavailability. Machine learning techniques can also enhance predictive accuracy by modeling complex patterns in docking and physicochemical data. Furthermore, expanding the scope to include multi-target screening could lead to the development of more effective therapeutic agents. Overall, this study lays a strong foundation for future *in silico*-guided drug development efforts.

References

1. Aamir, M., Singh, V. K., Dubey, M. K., Meena, M., Kashyap, S. P., Katari, S. K., ... & Singh, S. (2018). In silico prediction, characterization, molecular docking, and dynamic studies on fungal SDRs as novel targets for searching potential fungicides against Fusarium wilt in tomato. *Frontiers in pharmacology*, *9*, 1038.
2. Agrawal, A., Jain, N. K., Kumar, N., & Kulkarni, G. T. (2020). Molecular docking study to identify potential inhibitor of covid-19 main protease enzyme: An in-silico approach.
3. Auwal, S. M., Zainal Abidin, N., Zarei, M., Tan, C. P., & Saari, N. (2019). Identification, structure-activity relationship and in silico molecular docking analyses of five novel angiotensin I-converting enzyme (ACE)-inhibitory peptides from stone fish (*Actinopyga lecanora*) hydrolysates. *PLoS One*, *14*(5), e0197644.
4. Bursal, E., Yilmaz, M. A., Izol, E., Türkan, F., Atalar, M. N., Murahari, M., ... & Ahmad, M. (2021). Enzyme inhibitory function and phytochemical profile of *Inula discoidea* using in vitro and in silico methods. *Biophysical Chemistry*, *277*, 106629.
5. Chenafa, H., Mesli, F., Daoud, I., Achiri, R., Ghalem, S., & Neghra, A. (2022). In silico design of enzyme α -amylase and α -glucosidase inhibitors using molecular docking, molecular dynamic, conceptual DFT investigation and pharmacophore modelling. *Journal of Biomolecular Structure and Dynamics*, *40*(14), 6308-6329.
6. El Hassab, M. A., Ibrahim, T. M., Al-Rashood, S. T., Alharbi, A., Eskandrani, R. O., & Eldehna, W. M. (2021). In silico identification of novel SARS-COV-2 2'-O-methyltransferase (nsp16) inhibitors: structure-based virtual screening, molecular dynamics simulation and MM-PBSA approaches. *Journal of enzyme inhibition and medicinal chemistry*, *36*(1), 727-736.
7. Havranek, B., & Islam, S. M. (2021). An in silico approach for identification of novel inhibitors as potential therapeutics targeting COVID-19 main protease. *Journal of Biomolecular Structure and Dynamics*, *39*(12), 4304-4315.
8. Kumar, Y., Singh, H., & Patel, C. N. (2020). In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing. *Journal of infection and public health*, *13*(9), 1210-1223.
9. Ortiz, C. L. D., Completo, G. C., Nacario, R. C., & Nellas, R. B. (2019). Potential inhibitors of galactofuranosyltransferase 2 (GlfT2): molecular docking, 3D-QSAR, and in silico ADMETox studies. *Scientific reports*, *9*(1), 17096.

10. Riyaphan, J., Pham, D. C., Leong, M. K., & Weng, C. F. (2021). In silico approaches to identify polyphenol compounds as α -glucosidase and α -amylase inhibitors against type-II diabetes. *Biomolecules*, *11*(12), 1877.
11. Saber, F. R., Ashour, R. M., El-Halawany, A. M., Mahomoodally, M. F., Ak, G., Zengin, G., & Mahrous, E. A. (2021). Phytochemical profile, enzyme inhibition activity and molecular docking analysis of Feijoa sellowiana O. Berg. *Journal of enzyme inhibition and medicinal chemistry*, *36*(1), 618-626.
12. Saddala, M. S., & Huang, H. (2019). Identification of novel inhibitors for TNF α , TNFR1 and TNF α -TNFR1 complex using pharmacophore-based approaches. *Journal of translational medicine*, *17*, 1-16.
13. Sirous, H., Chemi, G., Gemma, S., Butini, S., Debyser, Z., Christ, F., ... & Brindisi, M. (2019). Identification of novel 3-hydroxy-pyran-4-one derivatives as potent HIV-1 integrase inhibitors using in silico structure-based combinatorial library design approach. *Frontiers in Chemistry*, *7*, 574.
14. Tahir, R. A., Bashir, A., Yousaf, M. N., Ahmed, A., Dali, Y., Khan, S., & Sehgal, S. A. (2020). In Silico identification of angiotensin-converting enzyme inhibitory peptides from MRJP1. *PloS one*, *15*(2), e0228265.
15. Xu, Z., Wu, C., Sun-Waterhouse, D., Zhao, T., Waterhouse, G. I., Zhao, M., & Su, G. (2021). Identification of post-digestion angiotensin-I converting enzyme (ACE) inhibitory peptides from soybean protein Isolate: Their production conditions and in silico molecular docking with ACE. *Food Chemistry*, *345*, 128855.